ストックスクリーナーアプリを入手
2.39
0.83%
-0.02
アフターアワーズ：
2.39
Nrx Pharmaceuticals Inc (NRXP) 最新ニュース
A High-Stakes Alliance Aims to Standardize Mental Health Care at Scale - MyChesCo
Will NRx Pharmaceuticals Inc. Equity Warrant stock reach all time highs in 20252026 world cup usa national team semifinals star players set piece tactics odds analysis preview - Улправда
NRx Pharmaceuticals (NASDAQ: NRXP) Partners With neurocare Group AG To Build Nationwide Neuroplastic Care Network - Digital Journal
NRx Pharmaceuticals and neurocare group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and Other Mental Health Afflictions - citybiz
D. Boral Capital Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions - Investing News Network
NRx and neurocare partner to create nationwide neuroplastic care network - Investing.com
NRx and neurocare partner to create nationwide neuroplastic care network By Investing.com - Investing.com Australia
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions - The Manila Times
Ulta Beauty To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Breakout Zone: Is NRx Pharmaceuticals Inc Equity Warrant stock in correction or buying zone2025 Growth vs Value & Safe Entry Trade Signal Reports - moha.gov.vn
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
NRx Pharmaceuticals Completes Debt Repayment, Ends 2025 Debt-Free - The Globe and Mail
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Short Interest Up 38.2% in December - MarketBeat
NRX Pharmaceuticals, Inc. Eliminates All Balance Sheet Debt - TradingView — Track All Markets
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine - Sentinel-Standard
NRx’s preservative-free ketamine reaches FDA review as company targets 2026 launch - MSN
New to The Street Broadcasts Nationwide Tonight on Bloomberg Television Featuring NeOnc ($NTHI), Metaterra Holdings Inc., CISO Global ($CISO), and NRx Pharmaceuticals ($NRXP) - Idaho Statesman
Earnings Update: Why hedge funds are buying NRx Pharmaceuticals Inc. stockPortfolio Update Summary & Risk Controlled Swing Trade Alerts - moha.gov.vn
NRX Pharmaceuticals Earnings Notes - Trefis
Bearish Setup: Will NRx Pharmaceuticals Inc. Equity Warrant stock outperform value stocksJuly 2025 Opening Moves & Daily Volume Surge Signals - moha.gov.vn
Is NRx Pharmaceuticals Inc. stock a top momentum play2025 Buyback Activity & Safe Capital Investment Plans - ulpravda.ru
Will NRx Pharmaceuticals Inc. stock pay special dividends2025 Retail Activity & Low Drawdown Momentum Ideas - Улправда
Can NRx Pharmaceuticals Inc. stock beat market expectations this quarterEarnings Summary Report & Growth Oriented Trading Recommendations - DonanımHaber
Published on: 2025-12-19 15:23:52 - DonanımHaber
Why NRx Pharmaceuticals Inc. Equity Warrant stock is a value investor pickWeekly Stock Summary & Risk Adjusted Buy/Sell Alerts - DonanımHaber
Can NRx Pharmaceuticals Inc. stock withstand economic slowdownWatch List & Technical Buy Zone Confirmations - DonanımHaber
Is NRx Pharmaceuticals Inc. stock a buy in volatile markets2025 Earnings Surprises & Real-Time Stock Price Movement Reports - Улправда
NRx Pharmaceuticals (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion - Digital Journal
Why NRx Pharmaceuticals Inc. Equity Warrant stock could see breakout soonJuly 2025 Short Interest & Stepwise Trade Execution Plans - Улправда
What momentum indicators show for NRx Pharmaceuticals Inc. stockTrade Risk Summary & High Return Stock Watch Alerts - Улправда
NRx Pharmaceuticals clears remaining $5.4 million debt By Investing.com - Investing.com Nigeria
Can NRx Pharmaceuticals Inc. stock rebound after recent weakness2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - Улправда
NRx Pharmaceuticals Announces Elimination of All Balance Sheet Debt Following Equity Conversion - citybiz
NRx Pharmaceuticals announces elimination of all balance sheet debt following equity conversion - Investing News Network
NRx Pharmaceuticals clears remaining $5.4 million debt - Investing.com
NRx Pharmaceuticals Completes Repayment of $5.4 Million Debt, Positioning Company for Growth in 2026 - Quiver Quantitative
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion - marketscreener.com
NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at HC Wainwright - MarketBeat
NRXP: HC Wainwright & Co. Reiterates Buy Rating with $40 Target - GuruFocus
HC Wainwright & Co. Reiterates NRx Pharmaceuticals (NRXP) Buy Recommendation - Nasdaq
Market Outlook: Does NRx Pharmaceuticals Inc stock trade at a discount to peersJuly 2025 Drop Watch & Stock Timing and Entry Methods - moha.gov.vn
[S-3/A] NRX Pharmaceuticals, Inc. Amended Shelf Registration Statement | NRXP SEC FilingForm S-3/A - Stock Titan
NRx Eyes Faster Commercial Path as NRX-101 Moves Into TMS-Enhanced Depression Treatment - MyChesCo
NRx’s Preservative-Free Ketamine Reaches FDA Review as Company Targets 2026 Launch - MyChesCo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Gross profit of NRX Pharmaceuticals, Inc. – HAM:B1Q - TradingView — Track All Markets
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Cash from financing activities of NRX Pharmaceuticals, Inc. – HAM:B1Q - TradingView
Is NRx Pharmaceuticals Inc. stock a bargain at current levelsMarket Rally & Weekly Top Stock Performers List - Newser
BTIG Research Reiterates Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals amends IND filing for NRX-101 to include use for TMS - MSN
Is NRx Pharmaceuticals Inc. Equity Warrant stock cheap compared to fundamentalsMarket Weekly Review & Verified Chart Pattern Trade Signals - Newser
NRXP Analyst Maintains Buy Rating with $34 Target | NRXP Stock N - GuruFocus
NRx Pharmaceuticals (NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment - NewMediaWire
NRx Pharmaceuticals (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment - Digital Journal
NRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
More Than 1 Million Suicidal Depression Cases Per Year May Be Treated by 2030 via New Indication for Augmentation of Transcranial Magnetic Stimulation: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - The Globe and Mail
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):